Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.75 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.68 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.68 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.67 |
| ▸ | HPGD | P15428 | 2/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.67 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.67 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.67 |
| ▸ | TP53 | P04637 | 1/20 | 0.65 |
| ▸ | CETP | P11597 | 1/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | RXFP1 | Q9HBX9 | 6/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.57 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.55 |
| ▸ | RXFP2 | Q8WXD0 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5243116 | 0.98 | SIRT2 (0.73) | SIRT2HDAC3HDAC1HDAC2ALDH1A1 | |
| SCHEMBL21724826 | 0.92 | SIRT2 (0.63) | SIRT2HDAC3HDAC1HDAC2ALDH1A1 | |
| SCHEMBL7814976 | 0.86 | ALDH1A1 (0.68) | SIRT2HDAC3HDAC1HDAC2ALDH1A1 | |
| SCHEMBL11732563 | 0.86 | ALDH1A1 (0.68) | SIRT2HDAC3HDAC1HDAC2ALDH1A1 | |
| SCHEMBL6374279 | 0.85 | SIRT2 (0.56) | SIRT2HDAC3HDAC1HDAC2ALDH1A1 | |
| SCHEMBL12323604 | 0.85 | CETP (0.77) | SIRT2HDAC3HDAC1HDAC2ALDH1A1 | |
| SCHEMBL28256535 | 0.85 | CETP (0.77) | SIRT2HDAC3HDAC1HDAC2ALDH1A1 | |
| SCHEMBL28258088 | 0.85 | CETP (0.77) | SIRT2HDAC3HDAC1HDAC2ALDH1A1 | |
| SCHEMBL7733805 | 0.84 | ALDH1A1 (0.71) | HDAC3HDAC1HDAC2ALDH1A1HPGD | |
| SCHEMBL11734795 | 0.84 | ALDH1A1 (0.70) | SIRT2HDAC3HDAC1HDAC2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11724983-B2 | Trisamide compounds and compositions comprising the same | MILLIKEN & COMPANY (US) | 2023-08-15 | — | — | US | disclosed |
| US-7452912-B2 | Fused ring heteroaryl and heterocyclic compounds which inhibit leukocyte adhesion mediated by VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 2008-11-18 | — | — | US | disclosed |
| US-20040029873-A1 | Fused ring heteroaryl and heterocyclic compounds which inhibit leukocyte adhesion mediated by VLA-4 | BIOGEN IDEC INTERNATIONAL HOLDING LTD. (BM) | 2004-02-12 | — | — | US | disclosed |
| US-6545003-B1 | Treating asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. | ELAN PHARMACEUTICALS, INC. | 2003-04-08 | — | — | US | disclosed |
| CN-1336921-A | Fused ring heteroaryl and heterocyclic compounds that inhibit VLA-4 mediated leukocyte adhesion | ELAN PHARM INC (US) | 2002-02-20 | — | — | CN | disclosed |
| EP-1147091-A2 | FUSED RING HETEROARYL AND HETEROCYCLIC COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | Elan Pharmaceuticals, Inc. (US) | 2001-10-24 | — | — | EP | disclosed |
| WO-2000043371-A2 | FUSED RING HETEROARYL AND HETEROCYCLIC COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 2000-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11724983-B2 | Trisamide compounds and compositions comprising the same | PTAR1, TIPRL, TCOF1 | SIRT2 2926/4885HDAC3 967/4885HDAC1 662/4885 |
| US-20040029873-A1 | Fused ring heteroaryl and heterocyclic compounds which inhibit leukocyte adhesion mediated by VLA-4 | VCAM1, ICAM1, LTB4R | SIRT2 3405/4885HDAC3 1515/4885HDAC1 877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.